Sindromi mielodisplastiche, due doppiette non migliorano la risposta rispetto alla sola chemio
Pharmastar Italy,
Due diverse combinazioni non sono riuscite a migliorare la risposta nei pazienti con sindromi mielodisplastiche ad alto rischio…
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Overview of attention for article published in Journal of Clinical Oncology, March 2017
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
Above-average Attention Score compared to outputs of the same age and source (61st percentile)
Mentioned by
- news
- 1 news outlet
- 20 X users
- patent
- 3 patents
- 1 Facebook page
- guideline
- 3 clinical guideline sources
Readers on
- mendeley
- 106 Mendeley